Indivior Inc.   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Richmond VA United States (2014)

Organization Overview

First Clinical Trial
2014
NCT00279565
First Marketed Drug
2014
buprenorphine
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Indivior Inc. | INDIVIOR INC | Indivior, PLC.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Alcohol Drinking (Phase 2)

Alcoholism (Phase 2)

Back Pain (Phase 2)

Cocaine-Related Disorders (Phase 2)

Disease (Phase 4)

Drug Overdose (Phase 3)

Emergencies (Phase 3)

Esophagitis, Peptic (Phase 2)

Gastroesophageal Reflux (Phase 2)

Hepatic Encephalopathy (Phase 4)

Hepatic Insufficiency (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Heroin Dependence (Phase 3)

Liver Failure (Phase 4)

Multiple Sclerosis (Phase 3)

Muscle Spasticity (Phase 2)

Opioid-Related Disorders (Phase 4)

Schizophrenia (Phase 4)

Sclerosis (Phase 3)

Spinal Cord Injuries (Phase 2)

Substance-Related Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 55
  • # of Trial APIs: 27